Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Regeneron’s fianlimab lung test approaches
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
J&J ramps up its bladder cancer battle
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
